Everest Medicines (HKSE:01952) Purchase Of Investment : HK$-4,162.2 Mil (TTM As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Purchase Of Investment?

Everest Medicines's purchase of investment for the six months ended in Jun. 2024 was HK$-2,202.3 Mil. It means Everest Medicines spent HK$2,202.3 Mil on purchasing investments. Everest Medicines's purchase of investment for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-4,162.2 Mil.

Compared with last quarter (HK$-1,959.9 Mil in Dec. 2023 ), Everest Medicines spent more money on purchasing investments in Jun. 2024 (HK$-2,202.3 Mil).

Everest Medicines Purchase Of Investment Historical Data

The historical data trend for Everest Medicines's Purchase Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Purchase Of Investment Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Purchase Of Investment

Get a 7-Day Free Trial

-1,296.05

-3,864.64

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Purchase Of Investment	Get a 7-Day Free Trial						-	-	-1,904.73	-1,959.92	-2,202.32

Everest Medicines Purchase Of Investment Calculation

Purchase of Investments represents cash outflow on the purchase of investments in securities.

Purchase Of Investment for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-4,162.2 Mil.

Everest Medicines Purchase Of Investment Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Purchase Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Purchase Of Investment

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Executives

Fu Wei	2307 Founder of a discretionary trust who can infl
Nova Aqua Limited	2201 Interest of corporation controlled by you
C-bridge Joint Value Creation Limited	2201 Interest of corporation controlled by you
Everest Management Holding Co., Ltd.	2101 Beneficial owner
Ra Capital Management, L.p.	2102 Investment manager
Kolchinsky Peter	2305 Beneficiary of a trust
Kolchinsky Anna Inge Leonore Haas	2202 Interest of your spouse
Ra Capital Healthcare Fund, L.p.	2101 Beneficial owner
Ra Capital Healthcare Fund Gp, Llc	2201 Interest of corporation controlled by you
Fu Wei	2307 Founder of a discretionary trust who can infl
Janchor Partners Limited	2102 Investment manager
C-bridge Capital Gp, Ltd.	2501 Other
Vistra Trust (singapore) Pte. Limited	2501 Other
C-bridge Capital Gp Iv, Ltd.	2201 Interest of corporation controlled by you
C-bridge Iv Investment Nine Limited	2101 Beneficial owner

Everest Medicines Headlines

No Headlines